MC-Sq-Cit-PAB-Dolastatin10 is primarily utilized in the field of targeted cancer therapy. It functions as a potent payload in antibody-drug conjugates (ADCs), where it is linked to a monoclonal antibody designed to recognize specific cancer cell markers. Once the antibody binds to the target cancer cells, the conjugate is internalized, and the dolastatin 10 component is released. Dolastatin 10 is a highly cytotoxic agent that disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells. This approach allows for the selective delivery of the cytotoxic agent to tumor cells, minimizing damage to healthy tissues and reducing systemic toxicity. Its application is particularly significant in treating various cancers, including lymphoma, breast cancer, and solid tumors, where precision medicine is critical for improving therapeutic outcomes.